期刊文献+

来那度胺对人宫颈癌SiHa细胞生长的影响 被引量:2

Effects of lenalidomide combined with cisplatin on the growth of SiHa cells
下载PDF
导出
摘要 目的探讨来那度胺及其联合顺铂对体外培养的人宫颈癌SiHa细胞增殖的抑制作用。方法体外培养SiHa细胞,实验设对照组、来那度胺组、顺铂组和来那度胺+顺铂联合组,各组药物处理后,用MTT法检测细胞生长抑制率,流式细胞术检测细胞周期分布。结果 MTT法检测结果显示,来那度胺与顺铂联用后对SiHa细胞的生长抑制作用较单用顺铂强(P<0.05),但来那度胺单独作用对SiHa细胞生长的影响与对照组比较无明显差异(P>0.05);流式细胞周期分析结果显示,来那度胺作用于SiHa细胞后,与对照组相比G1期细胞百分比增高(P<0.05),与顺铂联用后细胞周期阻滞作用增强(P<0.05)。结论来那度胺与顺铂联用可增强顺铂对SiHa细胞的生长抑制作用;来那度胺作用于SiHa细胞后可将细胞周期阻滞于G1期,与顺铂联用后细胞周期阻滞作用增强。 Objective To investigate whether lenalidomide alone or in combination with cisplatin can inhibit the growth of human cervical carcinoma SiHa cells in vitro. Methods Human cervical carcinoma SiHa cell line was cultured in vitro and then treated with different concentrations of lenalidomide, cisplatin, or lenalidomide combined with cisplatin in different groups. MTT was used to determine the growth inhibition ratio; flow cytometry was used to determine the effect of the drugs on cell cycle. Results The result of MTT showed that lenalidomide in combination with cisplatin enhanced the inhibitory effect of cisplatin on cell growth (P〈0. 05), but there was no significant difference between the lenalidomide group and control group (P〉 0.05). The result of flow cytometry showed that the percentage of G1 phase of lenalidomide group was significantly higher than that of control group (P〈0.05) and that the effect on cell cycle arrest could be enhanced when lenalidomide was used in combination with cisplatin (P〈0. 05). Conclusion Lenalidomide combined with cisplatin can enhance cisplatin's suppression on the growth of SiHa cells. Lenalidomide can arrest cell cycle in G1 phase, and when combined with cisplatin it has the synergistic effect on cell cycle arrest.
出处 《西安交通大学学报(医学版)》 CAS CSCD 北大核心 2013年第5期577-579,618,共4页 Journal of Xi’an Jiaotong University(Medical Sciences)
基金 陕西省科技发展计划项目(No.2012K13-02-03)~~
关键词 来那度胺 顺铂 人宫颈癌SiHa细胞 生长抑制率 细胞周期 lenalidomide cisplatin human cervical carcinoma SiHa cell growth inhibition ratio cell cycle
  • 相关文献

参考文献12

  • 1FERLAY J, BRAY F, PISANI P, et al. Cancer incidence, mortality and prevalence worldwide [G]. GLOBOCAN 2002. IARC Cancer Base 5(2.0), Lyon: IARC Press, 2004.
  • 2朱华,帅茨霞.年轻妇女宫颈癌134例初步分析[J].临床肿瘤学杂志,2004,9(4):383-385. 被引量:21
  • 3KUMAR S, RAJKUMAR SV. Thalidomide and lenalidomide in the treatment of multiple myeloma [J]. Eur J Cancer, 2006, 42(11) :1612-1622.
  • 4RICHARDSON PG, SCHLOSSMAN RL, WELLER E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma [J]. Blood, 2002, 100(9):3063-3067.
  • 5DHARMINDER C, AJITA VS, BRYAN C, et al. Combina- tion of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma [J]. Blood, 2010, 115(4),834-845.
  • 6ZHANG L, Q1AN ZZ, CAI Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo [J]. J Hematol, 2009, 84(9):553-559.
  • 7FUCHS O. Transcription factor nf-xb inhibitors as single thera- peutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies [J]. Curr Mol Pharmacol, 2010, 3(3):98-122.
  • 8MITSIADES N, MITSIADES CS, POULAKI V, et al. Apop- totic signaling induced by immunomodulatory thalidomide ana- logs [J]. Blood, 2002, 99(12) :4525-4530.
  • 9LAPALOMBELLA R, ANDRITSOS L, LIU Q, et al. Lena- lidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway [J]. Blood, 2010, 115(13) :2619-2629.
  • 10ROMANOV VS, BARDIN AA, ZUBOVA SG, et al. p21wAFI is required for complete oncogenic transformation of mouse embryo fibroblasts by E1Aad5 and c-Ha-ras oncogenes [J]. Biochimie, 2011, 93(9) :1408-1414.

二级参考文献10

  • 1Elliott PM, Tattersall MH, Coppleson M, et al. Changing character of cervical cancer in young women [J]. BMJ, 1989,298(6685) :1451 - 1456.
  • 2Ursin G, Pike MC, Preston M, et al. Sexual, reproductive, and other risk factors for adenocarcinoma of the cervix:results from a population-based case-control study (California, United States)[J]. Cancer Causes control, 1996,7(3) :391 -401.
  • 3ter-Harmsel B, Smedts F, Kuijpers J, et al. Relationship between human papillomavirus type 16 in the cervix and intraepithelial neoplasia[J]. Obstet Gynecol, 1999,93 (1) :46 -50.
  • 4Ferrera A, Velema, JP, Figueroa M, et al. Human papillomavirus infection, cervical dysplasia and invasive cervical cancer in Honduras: a case-control study [J]. Int J Cancer, 1999,82(6) :799 -803.
  • 5Clark MA, Naahas W, Markert RJ, et al. Cervical cancer:women aged 35 and younger compared to women aged 36 and older [J]. AM J Clin Oncol, 1991,14(4) :352 -356.
  • 6Shingleton HM, Bell MC, Fremgen A, et al. Is there really a difference in survival of women with squamous cell carcinoma,adenocarcinoma, and adenosquamous cell carcinoma of the cervix [J]. Cancer, 1995, 76(10):1948 -1955.
  • 7Delaloye J F. Pampallona S, Coucke PA, et al. Younger age as a bad prognostic factor in patients with carcinoma of the cervix [J]. Eur J Obstet Gynecol Reprod Biol, 1996,64(2):201 -205.
  • 8王志民,李琼,李筱文,刘淑美.青年妇女宫颈浸润癌77例临床分析[J].齐鲁肿瘤杂志,1999,6(1):38-39. 被引量:4
  • 9章文华,白萍,吴令英,马绍康.35岁以下妇女宫颈癌[J].中国肿瘤临床与康复,1999,6(6):39-41. 被引量:127
  • 10李筱梅,郑英,张庆.宫颈癌发病的年轻化趋势与人乳头状瘤病毒感染的关系[J].中国实用妇科与产科杂志,2000,16(12):741-742. 被引量:81

共引文献20

同被引文献18

  • 1Dimopoulos MA,Chen C,Spencer A,et al.Long-term followup onoverall survival from the MM-009 and MM010 phase III trialsof lenalidomide plus dexamethasone in patient with relapsed orrefractory multiple myeloma.[J].Leukemia,2009,23(l 1):2147-2152.
  • 2Gandhi K,fCang A,Capone J,et al.Dexamethasone synergizeswith lenalidomide to inhibit multiple myeloma tumorgrowth,but reduces lenalidomide-induced immunomodulationof T and NK cell function.Current Cancer Drug Targets[J].Blood,2010,10(2): 155-167.
  • 3Kneppers E,van der Holt B,Kerston MJ,et al.Lenalidomidemaintenance after nonmyeloablative allogeneic stem celltransplantation in multiple myeloma is not feasible: results of theHOVON 76 Trial.[J].Blood,2011,118(9):2413-2419.
  • 4Witzig TE,Vose JM,Zinzani PL,et al.An internationalphase II trial of single-agent lenalidomide for relapsed orrefractory aggressive B-cell non-Hodgkin's lymphoma[J] .AnnOncol,2011,22:1622-1627.
  • 5Chen CI,Bergsagel PL,Paul H,et al.Single-agent lenalidomidein the treatment of previously untreated chronic lymphocyticleukemia.J Clin Oncol,2011,29(9): 1175-1181.
  • 6Chen C,Paul H,Wang T,et al.Long-term follow-up of aphase 2 study of single agent lenalidomide in previouslyuntreated,symptomatic chronic lymphocytic leukemia(CLL)[J].ASH Annu Meet Abstr,2012,120:718.
  • 7Badoux XC,Keating MJ,Wen S,et al.Lenalidomide as initialtherapy of elderly patients with chronic lymphocytic leukemia.[J].Blood,2011,118(13):3489-3498.
  • 8Fehniger T,Larson S,Trinkaus K,et al.A phase 2 multicenterstudy of lenalidomide in relapsed or refractory classical Hodgkinlymphoma[J].Blood,2011,118(19):5119-5125.
  • 9Mandac I,Kolonic SO.Lenalidomide induced good clinicalresponse in a patient with multiple relapsed and refractoryHodgkin's lymphoma[J].J Hematol Oncol,2010,3(20): 1-3.
  • 10Prasanth G,Sarina PP,Aung N,et al.Phase I clinical trial oflenalidomide in combination with sorafenib in patients withadvanced cancer[J].Investigational New Drugs,2014,Vol.32(2):279-286.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部